Systems biology of tumor dormancy: Linking biology and mathematics on multiple scales to improve cancer therapy

Cancer Research

Volumn 72, Issue 9, 2012, Pages 2172-2175

  Enderling, Heiko ^a   Hahnfeldt, Philip ^a   Hlatky, Lynn ^a   Almog, Nava ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GROWTH; CANCER INVASION; CANCER STEM CELL; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CELL DEATH; CELL PROLIFERATION; CONFERENCE PAPER; HUMAN; IMMUNOREACTIVITY; INTRACELLULAR SIGNALING; MATHEMATICS; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; SYSTEMS BIOLOGY; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; TUMOR PROMOTION; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANIMALS; HUMANS; NEOPLASMS; SYSTEMS BIOLOGY;

EID: 84860500075     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-3269     Document Type: Conference Paper

References (25)

1. Folkman J, Kalluri R. Cancer without disease. Nature 2004;427:787. (Pubitemid 38297724)
2. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007;7:834-46. (Pubitemid 350006258)
3. Almog N. Molecular mechanisms underlying tumor dormancy. Cancer Lett 2010;294:139-46.
4. Bissell MJ, Hines WC. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 2011;17:320-9.
5. Almog N, Henke V, Flores L, Hlatky L, Kung AL, Wright RD, et al. Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis. FASEB J 2006;20:947-9.
6. Naumov GN, Bender E, Zurakowski D, Kang SY, Sampson D, Flynn E, et al. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst 2006;98:316-25. (Pubitemid 43338211)
7. Almog N, Ma L, Raychowdhury R, Schwager C, Erber R, Short S, et al. Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res 2009;69:836-44.
8. Indraccolo S, Minuzzo S, Masiero M, Pusceddu I, Persano L, Moserle L, et al. Cross-talk between tumor and endothelial cells involving the Notch3-Dll4 interaction marks escape from tumor dormancy. Cancer Res 2009;69:1314-23.
9. Serafin V, Persano L, Moserle L, Esposito G, Ghisi M, Curtarello M, et al. Notch3 signalling promotes tumour growth in colorectal cancer. J Pathol 2011;224:448-60.
10. Ghisi M, Corradin A, Basso K, Frasson C, Serafin V,Mukherjee S, et al. Modulation of microRNA expression in human T-cell development: targeting of NOTCH3 by miR-150. Blood 2011;117:7053-62.
11. Indraccolo S, Minuzzo S, Masiero M, Amadori A. Ligand-driven activation of the notch pathway in T-ALL and solid tumors: why Not(ch)? Cell Cycle 2010;9:80-5.
12. Masiero M, Minuzzo S, Pusceddu I, Moserle L, Persano L, Agnusdei V, et al. Notch3-mediated regulation ofMKP-1 levels promotes survival of T acute lymphoblastic leukemia cells. Leukemia 2011;25:588-98.
13. Hahnfeldt P, Panigrahy D, Folkman J, Hlatky L. Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res 1999;59:4770-5. (Pubitemid 29472873)
14. Saudemont A, Quesnel B. In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis. Blood 2004;104:2124-33. (Pubitemid 39297867)
15. Berthon C, Driss V, Liu J, Kuranda K, Leleu X, Jouy N, et al. In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors. Cancer Immunol Immunother 2010;59:1839-49.
16. Enderling H, Anderson AR, Chaplain MA, Beheshti A, Hlatky L, Hahnfeldt P. Paradoxical Dependencies of Tumor Dormancy and Progression on Basic Cell Kinetics. Cancer Res 2009;69:8814-21.
17. Enderling H, Hlatky L, Hahnfeldt P. Migration rules: tumours are conglomerates of self-metastases. Br J Cancer 2009;100:1917-25.
18. Sosa MS, Avivar-Valderas A, Bragado P, Wen HC, Aguirre-Ghiso JA. ERK1/2 and p38alpha/beta signaling in tumor cell quiescence: opportunities to control dormant residual disease. Clin Cancer Res 2011;17: 5850-7.
19. Adam AP, George A, Schewe D, Bragado P, Iglesias BV, Ranganathan AC, et al. Computational identification of a p38SAPK-regulated transcription factor network required for tumor cell quiescence. Cancer Res 2009;69:5664-72.
20. Felsher DW. MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms. Genes Cancer 2010;1:597-604.
21. Felsher DW. Reversing cancer from inside and out: oncogene addiction, cellular senescence, and the angiogenic switch. Lymphat Res Biol 2008;6:149-54.
22. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, et al. Identification of cells initiating human melanomas. Nature 2008;451:345-9.
23. Schatton T, Schutte U, Frank NY, Zhan Q, Hoerning A, Robles SC, et al. Modulation of T-cell activation by malignant melanoma initiating cells. Cancer Res 2010;70:697-708.
24. Uhr JW, Pantel K. Controversies in clinical cancer dormancy. Proc Natl Acad Sci U S A 2011;108:12396-400.
25. Goss PE, Chambers AF. Does tumour dormancy offer a therapeutic target? Nat Rev Cancer 2010;10:871-7.